| Literature DB >> 28514685 |
Evan M Cale1, Jason Gorman1, Nathan A Radakovich1, Ema T Crooks2, Keiko Osawa2, Tommy Tong3, Jiaqi Li1, Raju Nagarajan4, Gabriel Ozorowski5, David R Ambrozak1, Mangai Asokan1, Robert T Bailer1, Anthony K Bennici1, Xuejun Chen1, Nicole A Doria-Rose1, Aliaksandr Druz1, Yu Feng6, M Gordon Joyce1, Mark K Louder1, Sijy O'Dell1, Courtney Oliver1, Marie Pancera1, Mark Connors7, Thomas J Hope8, Thomas B Kepler9, Richard T Wyatt6, Andrew B Ward5, Ivelin S Georgiev10, Peter D Kwong11, John R Mascola12, James M Binley13.
Abstract
Most HIV-1-specific neutralizing antibodies isolated to date exhibit unusual characteristics that complicate their elicitation. Neutralizing antibodies that target the V1V2 apex of the HIV-1 envelope (Env) trimer feature unusually long protruding loops, which enable them to penetrate the HIV-1 glycan shield. As antibodies with loops of requisite length are created through uncommon recombination events, an alternative mode of apex binding has been sought. Here, we isolated a lineage of Env apex-directed neutralizing antibodies, N90-VRC38.01-11, by using virus-like particles and conformationally stabilized Env trimers as B cell probes. A crystal structure of N90-VRC38.01 with a scaffolded V1V2 revealed a binding mode involving side-chain-to-side-chain interactions that reduced the distance the antibody loop must traverse the glycan shield, thereby facilitating V1V2 binding via a non-protruding loop. The N90-VRC38 lineage thus identifies a solution for V1V2-apex binding that provides a more conventional B cell pathway for vaccine design.Entities:
Keywords: B cell ontogeny; CDRH3; HIV; NAb; V1V2; VLP; antibody; bnAb; glycan shield; neutralization; trimer; vaccine-design template
Mesh:
Substances:
Year: 2017 PMID: 28514685 PMCID: PMC5512451 DOI: 10.1016/j.immuni.2017.04.011
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745